• Have any questions?
  • info@mpncancerconnection.org
Screen Shot 2016-03-16 at 5.15.52 PMScreen Shot 2016-03-16 at 5.15.52 PMScreen Shot 2016-03-16 at 5.15.52 PMScreen Shot 2016-03-16 at 5.15.52 PM
  • Our Mission
  • About
    • Our team
    • Info
    • David Wallace BioDavid Wallace - MPN Patient Advocate

      David Wallace

      Founder & CEO of MPN Cancer Connection and PV Reporter | Patient Advocate

      When David was diagnosed with PV in 2009, at the age of 47, he soon learned there was limited and often conflicting information available on Myeloproliferative Neoplasms (MPNs). He also realized early on in his diagnosis, the importance of advocating for himself to best manage his polycythemia vera (PV). David was grateful for the early support and guidance of fellow MPN patients on his journey and wanted a way to give back to the MPN community. With a professional background in business administration and sociology, David has a passion for finding solutions and helping others. In 2013, David used his skill set to create PV Reporter,
      a comprehensive patient-focused website for MPNs. David refers to his site as a hub for patients to begin to research their cancer. Whether a patient, caregiver or healthcare provider, PV Reporter offers visitors a wealth of educational resources, patient stories, articles, and the latest news on the treatment for MPNs, helping MPN patients and their caregivers stay informed, connected and empowered. In 2015, along with the help of others, David founded a non-profit MPN Cancer Connection (MPN-CC), a patient-led 501©3 formed to create awareness that MPN patients are “cancer patients” and should have complete access to local and national programs and benefits. David’s philosophy is to educate patients to become their own advocates so that they can make informed decisions on their treatment. David’s dedication to the MPN community is further evidenced through his work and awards:
      • Selected to endorse 2018 NCCN guidelines for MPN patients by MPN Cancer Connection
      • Selected to represent the United States as a patient advocate by MPNs Advocate Network International Conference 2016-2019
      • Recipient of MPN Hero Award 2016
      • Published in MD Anderson Cancer Center MPN Focus Newsletter Fall 2016
      • Appearance on “The Doctors” TV show in 2015 to promote MPN awareness
      • Awarded Press Credentials for American Society of Hematology Conference 2014-2019
      • Contributor to Patient Power MPN educational videos
      David lives in Charlotte, North Carolina. When he’s not working, David enjoys spending time with family, listening to live music, attending outdoor festivals, watching the Carolina Panthers, riding his motorcycle, traveling and of course having his beloved Aussiedoodle Bailey by his side.
  • Resources
    • Partners
    • Corporate Sponsors
    • Groups
  • Our Vision
  • Donate
  • Blog
  • Contact
  • Terms
  • Privacy
  • Partners
  • About
  • Contact
Donate

Clinical Trial Finder

Clinical Trial Finder

Search Results

De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination

Study Purpose

This study is constituted of two stage: Treatment-Free Remission 1 (TFR1) stage and Treatment-Free Remission 2 (TFR2) stage. The purpose of the TFR1 stage is to assess the effect of nilotinib reduced to half the standard dose for 12 months on treatment-free remission in patients with Chronic Myeloid Leukemia

  • - Chronic Phase (CML-CP) treated with first-line nilotinib who reached a sustained deep molecular response before entering the study.
The purpose of the TFR2 stage is to evaluate whether the use of asciminib in combination with nilotinib after failure of a first attempt at TFR can lead to higher and more durable TFR rates after a second attempt at TKI discontinuation than those reported in other studies.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 99 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria TFR1 stage: 1. Male and female patients 18 years or older. 2. Diagnosis of CML-CP according to the World Health Organization. 3. Patients with CML-CP under first-line treatment with nilotinib at the approved daily dose of 300 mg BID mg for at least 3 calendar years. Note: At study entry, an ongoing treatment at a dose ≥400 mg per day is allowed. 4. Sustained DMR defined as ≥ MR 4.0 (BCR-ABL level ≤0.01% IS) in all of the last 4 BCR-ABL RQ-PCR assessments with a minimum interval between each assessment of 3 months and a maximum interval of 6 months. 5. Patient must meet the following laboratory values at the screening visit:

  • - Absolute Neutrophil Count ≥1.0 x 109/L.
  • - Platelets ≥75 x 109/L.
  • - Hemoglobin (Hgb) ≥ 9 g/dL.
  • - Serum creatinine < 1.5 mg/dL.
  • - Aspartate transaminase (AST) ≤ 3.0 x Upper Limit of Normal (ULN) - Alanine transaminase (ALT) ≤ 3.0 x ULN.
  • - Serum lipase ≤ 2 x ULN.
6. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0-2. 7. Study subjects must be able to comply with study procedures and follow-up examinations. Exclusion Criteria TFR1 stage: 1. Patients with known atypical transcript. 2. CML treatment resistant mutation(s) (T315I, E255K/V, Y253H, F359C/V) detected if testing was done in the past (there is no requirement to perform mutation testing at study entry if it was not done in the past). 3. Dose reductions/interruptions due to neutropenia or thrombocytopenia in the past 6 months. 4. Patient ever attempted to permanently discontinue nilotinib treatment. 5. Known impaired cardiac function including any one of the following:
  • - Inability to determine QT interval on ECG.
  • - Complete left bundle branch block.
  • - Long QT syndrome or a known family history of long QT syndrome.
  • - History of or presence of clinically significant ventricular or atrial tachyarrhythmias.
  • - Clinically significant resting bradycardia.
  • - QTcF > 480 msec.
  • - History or clinical signs of myocardial infarction within 1 year prior to study entry.
  • - History of unstable angina within 1 year prior to study entry.
  • - Other clinically significant heart disease (e.g. uncontrolled congestive heart failure or uncontrolled hypertension) 6.
Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol. 7. History of acute pancreatitis within 1 year prior to study entry or past medical history of chronic pancreatitis. 8. Known presence of a significant congenital or acquired bleeding disorder unrelated to cancer. 9. History of other active malignancy within 5 years prior to study entry except for previous or concomitant basal cell skin cancer, previous cervical carcinoma in situ treated curatively. 10. Patients who have not recovered from prior surgery. 11. Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks of Day 1. 12. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery). 13. Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry. 14. Patients actively receiving therapy with herbal medicines that are strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry. These herbal medicines may include Echinacea, (including E. purpurea, E. angustifolia and E. pallida), Piperine, Artemisinin, St. John's Wort, and Ginkgo. 15. Pregnant or nursing (lactating) women. 16. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for at least 14 days after stopping medication. There is a limited amount of data on pregnancies in patients while attempting treatment-free remission (TFR). If pregnancy is planned during the TFR phase, the patient must be informed of a potential need to re-initiate treatment with nilotinib during pregnancy. Highly effective contraception methods include:
  • - Total abstinence (when this is in line with the preferred and usual lifestyle of the subject.
Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
  • - Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment.
In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
  • - Male sterilization (at least 6 months prior to screening).
The vasectomized male partner should be the sole partner for that subject.
  • - Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before starting the study. Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential. Inclusion Criteria TFR2 stage: 1. Signed informed consent to the TFR2 stage from the patient or from his/her legal representative. 2. Male and female patients 18 years or older. 3. Diagnosis of CP-CML according to the WHO and no previous history of progression to AP/BP CML. 4. First-line treatment with nilotinib for at least 3 calendar years, followed by first TFR attempt. 5. Failed first TFR attempt followed by at least 1 year of nilotinib retreatment before enrollment in TFR2 stage. 6. MR4 or better (BCR-ABL ≤ 0.01% IS) assessed at screening. 7. Patient must meet the following laboratory values at the reinduction screening visit: 1. Absolute neutrophil count ≥1.0 x 109/L. 2. Platelets ≥75 x 109/L. 3. Hemoglobin (Hgb) ≥ 9 g/dL. 4. Serum creatinine < 1.5 mg/dL. 5. Total bilirubin ≤ 2 x ULN except for patients with Gilbert's syndrome who may only be included if total bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN. 6. AST ≤ 3.0 x ULN. 7. ALT ≤ 3.0 x ULN. 8. Alkaline phosphatase ≤ 2.5 x ULN. 9. Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN
  • - ≤ 1.5 x ULN, value must be considered not clinically significant and not associated with risk factors for acute pancreatitis.
10. Serum levels of potassium, magnesium, total calcium within the normal limits. Correction of electrolytes levels with supplements to fulfil enrolment criteria is allowed. 8. ECOG performance status 0-2. 9. Study subjects must be able to comply with study procedures and follow-up examinations. Exclusion Criteria TFR2 stage: 1. Patients with known atypical transcript. 2. CML treatment resistant mutation(s) (T315I, E255K/V, Y253H, F359C/V) detected if testing was done in the past (there is no requirement to perform mutation testing at study entry if it was not done in the past). 3. Dose reductions/interruptions due to neutropenia or thrombocytopenia in the past 6 months. 4. Known impaired cardiac function including any one of the following:
  • - Inability to determine QT interval on ECG.
  • - Complete left bundle branch block.
  • - Long QT syndrome or a known family history of long QT syndrome.
  • - History of or presence of clinically significant ventricular or atrial tachyarrhythmias.
  • - Clinically significant resting bradycardia.
  • - QTcF > 450 msec (male) or > 460 msec (female) - History or clinical signs of myocardial infarction within 1 year prior to study entry.
  • - History of unstable angina within 1 year prior to study entry.
  • - Other clinically significant heart disease (e.g. uncontrolled congestive heart failure or uncontrolled hypertension) 5.
Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol. 6. History of acute pancreatitis within 1 year prior to study entry or past medical history of chronic pancreatitis. 7. Known presence of a significant congenital or acquired bleeding disorder unrelated to cancer. 8. History of other active malignancy within 5 years prior to study entry except for previous or concomitant basal cell skin cancer, previous cervical carcinoma in situ treated curatively. 9. Patients who have not recovered from prior surgery. 10. Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks. 11. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery). 12. Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry. 13. Patients actively receiving therapy with herbal medicines that are strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry. These herbal medicines may include Echinacea, (including E. purpurea, E. angustifolia and E. pallida), Piperine, Artemisinin, St. John's Wort, and Ginkgo. 14. Pregnant or nursing (lactating) women. 15. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for at least 14 days after stopping medication. There is a limited amount of data on pregnancies in patients while attempting treatment-free remission (TFR). If pregnancy is planned during the TFR phase, the patient must be informed of a potential need to re-initiate treatment with nilotinib during pregnancy. Highly effective contraception methods include:
  • - Total abstinence (when this is in line with the preferred and usual lifestyle of the subject.
Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
  • - Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment.
In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
  • - Male sterilization (at least 6 months prior to screening).
The vasectomized male partner should be the sole partner for that subject.
  • - Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before starting the study. Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03874858
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Novartis Pharmaceuticals
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Italy
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Chronic Myeloid Leukemia
Additional Details

This is a prospective, single arm, phase II study constituted of two stage: Treatment-Free Remission 1 (TFR1) stage and Treatment-Free Remission 2 (TFR2) stage. The TFR1 stage is made up of 4 periods: 1. Screening (week -4

  • - week 0) 2.
Nilotinib consolidation (week 0
  • - week 48): Patients will be treated with nilotinib 300 mg QD.
At the end or during the consolidation period, patients will proceed as follows:
  • - Patients with sustained DMR at the end of the consolidation phase will enter the treatment-free remission (TFR1) and nilotinib will be discontinued.
If two or more consecutive quarterly BCR-ABL RQ-PCR assessments are not performed or results are not available, the patient will not be eligible for TFR1 period and will be treated with nilotinib 300 mg QD until the end of the TFR1 stage (week 144).
  • - Patients with loss of major molecular response (MMR) at any time during the consolidation phase will enter the follow-up period and will return to the standard nilotinib administration regimen (nilotinib 300 mg BID) until the end of the TFR1 stage (week 144).
  • - Patients with more than MMR, but without meeting the definition of sustained DMR, will remain in the consolidation phase and will be treated with nilotinib 300 mg QD until the end of the TFR1 stage (week 144).
3. Nilotinib treatment-free remission (TFR1) (week 48
  • - week 144): During the TFR1 period, BCR-ABL levels will be monitored until the end of the TFR1 stage (week 144) 4.
Follow up: Patients who remain on half-dose nilotinib after week 48 and patients with loss of MMR at any time during the study will enter follow-up until week 144. Patients discontinued from the treatment for any reason will be followed for survival information until week 144. All patients still on study treatment at the end of the study will be transitioned to prescription nilotinib. The TFR2 stage will include two cohorts; an internal cohort made up of patients who participated in the TFR1 stage of this study, and an external cohort of patients who failed a first attempt at TFR with nilotinib outside of this study. The TFR2 stage is made up of 4 periods: 1. Screening for reinduction. 2. Reinduction (week 0-96): Patients will be treated with asciminib 40 mg BID + nilotinib 300 mg BID for 96 weeks. Patients will proceed as follows:
  • - Patients with sustained DMR at the end of reinduction will enter TFR2 and asciminib + nilotinib will be discontinued.
If two or more consecutive quarterly BCR-ABL RQ-PCR assessments are not performed or results are not available, the patient will not be eligible for TFR2.
  • - Patients not eligible for TFR2 but with more than an MMR continue treatment with asciminib + nilotinib until the end of reinduction (week 96) and then continue nilotinib monotherapy at 300 mg BID until the end of the TFR2 stage (week 144).
  • - Patients with loss of MMR at any time during reinduction or during nilotinib monotherapy will be discontinued from the study.
3. Asciminib+nilotinib treatment-free remission (TFR2) (week 96-week 144): During the TFR2 period, BCR-ABL levels will be monitored every month for one year. 4. Follow up: Patients with loss of MMR during TFR2 and patients not eligible for TFR2 but with more than an MMR will be treated with nilotinib 300 mg BID and monitored until week 144. If MMR loss occurs during reinduction or during nilotinib monotherapy, patients will be discontinued from the study and treated according to clinical practice.

Arms & Interventions

Arms

Experimental: TFR1 stage- Nilotinib

During TFR1 stage, all patients will be treated with nilotinib 300 mg QD for up to 48 weeks (consolidation period). Patients with sustained DMR at the end of the consolidation period will enter the TFR1 period and nilotinib will be discontinued. Patients with loss of MMR will return to the standard nilotinib administration Patients with ≥ MMR, but without sustained DMR at the end of the consolidation period will be treated with nilotinib 300 mg QD

Experimental: TFR2 stage- Nilotinib+Asciminib

During the TFR2 stage, participants will be treated with nilotinib and asciminib for up to 96 weeks (reinduction period). Patients with sustained DMR at the end of reinduction will enter TFR2 and asciminib + nilotinib will be discontinued. Patients with ≥ MMR, but without sustained DMR, at the end of the reinduction, will be treated with nilotinib monotherapy at 300 mg BID until the end of the TFR2 stage. Patients with loss of MMR at any time during reinduction or during nilotinib monotherapy will be discontinued from the study.

Interventions

Drug: - Nilotinib

Nilotinib oral 300 mg QD hard capsules

Drug: - Nilotinib

Nilotinib oral 300 mg BID hard capsules

Drug: - Asciminib

Asciminib orally at a dose of 40 mg BID film-coated tablets (FCT)

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Novartis Investigative Site, Bari, BA, Italy

Status

Recruiting

Address

Novartis Investigative Site

Bari, BA, 70124

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Bologna, BO, Italy

Status

Recruiting

Address

Novartis Investigative Site

Bologna, BO, 40138

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Cagliari, CA, Italy

Status

Recruiting

Address

Novartis Investigative Site

Cagliari, CA, 09126

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Catania, CT, Italy

Status

Recruiting

Address

Novartis Investigative Site

Catania, CT, 95123

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Catanzaro, CZ, Italy

Status

Recruiting

Address

Novartis Investigative Site

Catanzaro, CZ, 88100

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Firenze, FI, Italy

Status

Recruiting

Address

Novartis Investigative Site

Firenze, FI, 50134

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Genova, GE, Italy

Status

Recruiting

Address

Novartis Investigative Site

Genova, GE, 16132

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Milano, MI, Italy

Status

Recruiting

Address

Novartis Investigative Site

Milano, MI, 20122

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Milano, MI, Italy

Status

Recruiting

Address

Novartis Investigative Site

Milano, MI, 20162

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Palermo, PA, Italy

Status

Recruiting

Address

Novartis Investigative Site

Palermo, PA, 90127

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Palermo, PA, Italy

Status

Recruiting

Address

Novartis Investigative Site

Palermo, PA, 90146

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Pescara, PE, Italy

Status

Recruiting

Address

Novartis Investigative Site

Pescara, PE, 65124

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Perugia, PG, Italy

Status

Recruiting

Address

Novartis Investigative Site

Perugia, PG, 06100

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Pisa, PI, Italy

Status

Recruiting

Address

Novartis Investigative Site

Pisa, PI, 56126

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Ravenna, RA, Italy

Status

Withdrawn

Address

Novartis Investigative Site

Ravenna, RA, 48100

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Reggio Emilia, RE, Italy

Status

Recruiting

Address

Novartis Investigative Site

Reggio Emilia, RE, 42123

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Roma, RM, Italy

Status

Recruiting

Address

Novartis Investigative Site

Roma, RM, 00144

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Roma, RM, Italy

Status

Recruiting

Address

Novartis Investigative Site

Roma, RM, 00161

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Roma, RM, Italy

Status

Recruiting

Address

Novartis Investigative Site

Roma, RM, 00168

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Salerno, SA, Italy

Status

Recruiting

Address

Novartis Investigative Site

Salerno, SA, 84131

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Siena, SI, Italy

Status

Recruiting

Address

Novartis Investigative Site

Siena, SI, 53100

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Orbassano, TO, Italy

Status

Recruiting

Address

Novartis Investigative Site

Orbassano, TO, 10043

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Torino, TO, Italy

Status

Recruiting

Address

Novartis Investigative Site

Torino, TO, 10126

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Torino, TO, Italy

Status

Recruiting

Address

Novartis Investigative Site

Torino, TO, 10128

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Udine, UD, Italy

Status

Withdrawn

Address

Novartis Investigative Site

Udine, UD, 33100

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Verona, VR, Italy

Status

Recruiting

Address

Novartis Investigative Site

Verona, VR, 37126

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Napoli, Italy

Status

Recruiting

Address

Novartis Investigative Site

Napoli, , 80131

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Napoli, Italy

Status

Recruiting

Address

Novartis Investigative Site

Napoli, , 80132

Site Contact

novartis.email@novartis.com

+41613241111

Novartis Investigative Site, Novara, Italy

Status

Recruiting

Address

Novartis Investigative Site

Novara, , 28100

Site Contact

novartis.email@novartis.com

+41613241111

Powered By
The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Recent Posts

  • Contemporary Approach CALR Positive MPNs
  • 9 Tips to Reduce MPN Fatigue
  • Common Clinical Trial Acronyms and Abbreviations
  • Understanding the Phases of Clinical Trials
  • 4th Angel providing one-on-one support services for MPN Patients
  • Serving the MPN cancer community with support services




Sign up for our Newsletter

Subscribers will receive updates from MPN-CC and PV Reporter!
* = required field

RSS News

  • Inflammatory Microenvironment & Specific T-Cells in MPNs
  • Covid-19 Vaccines FAQs for Patients and Caregivers
  • Precision Medicine and Gene Mutations in MPNs
  • New MPN Drug Treatments in Development
© 2021 MPN Cancer Connection. All Rights Reserved.
  • Terms
  • Privacy
  • Partners
  • About
  • Contact
MPN Cancer Connection
Malcare WordPress Security